At what enterprise value was THERAVIA acquired in 2022?

You can find the full valuation details of THERAVIA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of THERAVIA when it was acquired by MERIEUX EQUITY PARTNERS?

The exact EV/EBITDA multiple for THERAVIA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was THERAVIA acquired by MERIEUX EQUITY PARTNERS?

THERAVIA was acquired by MERIEUX EQUITY PARTNERS in 2022.

What was the revenue of THERAVIA at the time of the deal?

The revenue of THERAVIA at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the THERAVIA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the THERAVIA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/nos-exclus/addmedica-et-laboratoires-ctrs-fusionnent-grace-a-merieux-ep-1777418

← DATABASE

Home Database Healthcare & PharmaTHERAVIA

07/2022

MERIEUX EQUITY PARTNERS takes majority stake in THERAVIA

FRANCE Life Sciences / Pharma & Biotech / Generics / Labs REV 25M - 50M EUR

Context

Healthcare-focused investment firm Mérieux Equity Partners has completed the strategic merger of two of its existing portfolio companies, Addmedica and Laboratoires CTRS, creating a new consolidated entity named Theravia Pharma. As part of this corporate combination, the sponsor—which already held existing stakes in both businesses—elected to significantly increase its overall equity position. Mérieux EP rolled over its historical shares and convertible bonds while simultaneously acquiring additional equity, notably buying out the exiting founders of Addmedica. This move enabled the fund to step up its ownership and secure a majority controlling stake of approximately 70% in the newly formed group. The equity enhancement and the refinancing of existing credit facilities were supported by the successful raising of new senior debt.

THERAVIA, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Theravia is an international pharmaceutical laboratory specializing in rare and neglected diseases, formed in 2022 following the merger of Addmedica and CTRS, with the aim of addressing the unmet medical needs of patients suffering from these complex conditions. The company has notably developed treatments such as Orphacol for congenital defects in primary bile acid synthesis and Siklos for sickle cell disease, a hereditary disorder affecting red blood cells. Theravia has a commercial presence in several countries, including 17 for Siklos and 23 for Orphacol, and generates nearly half of its revenue internationally, demonstrating its growth potential and strategic positioning in the field of rare diseases.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Other operations with THERAVIA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2025	NORGINE	THERAVIA	FRANCE	Life Sciences	Private equity firm Mérieux Equity Partners has entered into a definitive agreement to divest its controlling equity stake in the pharmaceutical laboratory Theravia to the Dutch group Norgine, a portfolio company backed by Goldman Sachs Asset Management

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of THERAVIA by MERIEUX EQUITY PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: theravia

Acquirer: merieux equity partners